0
The Cambridge Phenomenon:
Solexa, Genome Sequencing
ViaCyte, Stem Cells for Diabetes
John West
CEO, ViaCyte, Inc
Previousl...
Solexa Technology Flow
Reagents, Instruments, Software, Sequences
2The Cambridge Phenomenon
Conference, Oct 5, 2010
Just a few of
the UK
team...
3The Cambridge Phenomenon
Conference, Oct 5, 2010
SG Cowen
Investment bankers
New York
Solexa,
Little Chesterford
Essex
Financing
In 2005, once Solexa became a US
Nasdaq-li...
5The Cambridge Phenomenon
Conference, Oct 5, 2010
6The Cambridge Phenomenon
Conference, Oct 5, 2010
...said Mr. West..."By sequencing a family of at least four we
can ... interpret compound heterozygote variations in genes...
The Cambridge Phenomenon
Conference, Oct 5, 2010
8
3.5 M SNPs (350k novel)
9,707 non-synonymoous
SNPs per HPGP
2,428 trait...
.....
9The Cambridge Phenomenon
Conference, Oct 5, 2010
10The Cambridge Phenomenon
Conference, Oct 5, 2010
Market Scale
Anecdotes
11The Cambridge Phenomenon
Conference, Oct 5, 2010
Projected Adoption of Genome-
Scale DNA sequencing
• Approx. 30 – 50 named individuals sequenced so far
• A few research-c...
Stem Cell-Derived Therapy for Diabetes
13The Cambridge Phenomenon
Conference, Oct 5, 2010
Financing Development of Stem Cell Derived Therapies
• Technology risk declining, but regulatory timing risk remains a
cha...
Thank-you for your attention
John West
ViaCyte, Inc
jwest@viacyte.com
+1 858 455 3677
15The Cambridge Phenomenon
Conferenc...
Upcoming SlideShare
Loading in...5
×

John West's presentation

830

Published on

John West's presentation at the Cambridge Phenomenon Conference

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
830
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "John West's presentation"

  1. 1. The Cambridge Phenomenon: Solexa, Genome Sequencing ViaCyte, Stem Cells for Diabetes John West CEO, ViaCyte, Inc Previously CEO, Solexa 1The Cambridge Phenomenon Conference, Oct 5, 2010
  2. 2. Solexa Technology Flow Reagents, Instruments, Software, Sequences 2The Cambridge Phenomenon Conference, Oct 5, 2010
  3. 3. Just a few of the UK team... 3The Cambridge Phenomenon Conference, Oct 5, 2010
  4. 4. SG Cowen Investment bankers New York Solexa, Little Chesterford Essex Financing In 2005, once Solexa became a US Nasdaq-listed company, it raised $97.5M in 8 months. 4The Cambridge Phenomenon Conference, Oct 5, 2010
  5. 5. 5The Cambridge Phenomenon Conference, Oct 5, 2010
  6. 6. 6The Cambridge Phenomenon Conference, Oct 5, 2010
  7. 7. ...said Mr. West..."By sequencing a family of at least four we can ... interpret compound heterozygote variations in genes - those cases where multiple variations in a single gene, but on opposing chromosome copies, combine as a virtual homozygote. I expect that these are much more prevalent, and the source of much more phenotypic variability, than previously understood. Working with medical geneticists, we look forward to exploring this new visibility into factors influencing our future health." 7The Cambridge Phenomenon Conference, Oct 5, 2010
  8. 8. The Cambridge Phenomenon Conference, Oct 5, 2010 8 3.5 M SNPs (350k novel) 9,707 non-synonymoous SNPs per HPGP 2,428 trait-associated loci per HPGP report (1,716 unique) GET- Evidence (28) OMIM (99) HuGENet GWAS (1,133) SNPedia (326) HGMD (282) Pharm GKB (28) Other Hypotheses (532) Genome Analysis Summary to Date John West 9/30/2010 2 loci in same drug metabolism gene re Nexium: Slow metaboliser Ultra Fast Metabolizer Also compound heterozygocity Factor 5 Leiden & Compound heterozygocity Associated trait description includes “diabetes” (95) Type 1 (48) Type 2 (45) Diabetes non- specific (2)
  9. 9. ..... 9The Cambridge Phenomenon Conference, Oct 5, 2010
  10. 10. 10The Cambridge Phenomenon Conference, Oct 5, 2010
  11. 11. Market Scale Anecdotes 11The Cambridge Phenomenon Conference, Oct 5, 2010
  12. 12. Projected Adoption of Genome- Scale DNA sequencing • Approx. 30 – 50 named individuals sequenced so far • A few research-clinical cases have saved lives, esp in cancer • Current capacity based on installed base of Illumina instruments is 25 – 50,000 complete human genomes per year • Source of the gap: – Research human genome sequencing is much larger – Many other research uses of DNA sequencing capacity – Price still falling: $2,000 by late 2011 ? • Medical interpretation improving & action-ability transitioning: – Statistical association (probabilities of future disease) – Mechanism of action – Intervention to prevent or better treat • Potential for ethical issues declines as this transition is made 12The Cambridge Phenomenon Conference, Oct 5, 2010
  13. 13. Stem Cell-Derived Therapy for Diabetes 13The Cambridge Phenomenon Conference, Oct 5, 2010
  14. 14. Financing Development of Stem Cell Derived Therapies • Technology risk declining, but regulatory timing risk remains a challenge for investors & pharma – Geron on clinical hold for almost 2 years – US Federal Government policy adds to perception of risk • California Institute of Regenerative Medicine (CIRM) as a model for funding (aka Proposition 71): – ViaCyte awarded $26M – of the scale needed for a major development – Additional $25M possible for clinical trials – Most CIRM funding has gone to universities • Cost of initial developments are only affordable for major medical reimbursement categories, or for springboards to them 14The Cambridge Phenomenon Conference, Oct 5, 2010
  15. 15. Thank-you for your attention John West ViaCyte, Inc jwest@viacyte.com +1 858 455 3677 15The Cambridge Phenomenon Conference, Oct 5, 2010
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×